Company Profile
Orion develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and globally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer.
Its portfolio also includes Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease, Burana for inflammatory pain, Divina series for menopausal symptoms, Simdax for acute decompensated heart failure, Fareston for breast cancer, Quetiapine products for antipsychotic, Trexan for rheumatoid arthritis and cancer, Easyhaler product portfolio for asthma and COPD, and Dexdor, Precedex, and Dexmedetomidine products for human use
Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.
Additionally, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie. Its portfolio also includes APIs for generic compounds and proprietary products, as well as contract manufacturing services, and markets and sells drugs and products manufactured by other companies
Self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products. It also offers its products online. The company has a licensing agreement with Tenax Therapeutics, Inc. to develop oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) Bayer for the development and commercialisation of darolutamide Nubeqa. Founded in 1917, Orion is headquartered in Espo, Finland.